Evidence map›Paper›PMID 35983519›Full record

ArticleVaccine: X2022

Implementation of an outbreak response vaccination campaign with typhoid conjugate vaccine - Harare, Zimbabwe, 2019.

M Poncin, J Marembo, P Chitando, N Sreenivasan, I Makwara, Z Machekanyanga, W Nyabyenda, I Mukeredzi, M Munyanyi, A Hidle and 15 more

Abstract read
In one paragraph

Article in Vaccine: X, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

M PoncinWorld Health Organization, Geneva, Switzerland.
J MaremboMinistry of Health and Child Care, Harare, Zimbabwe.
P ChitandoHarare City Health Department, Harare, Zimbabwe.
N SreenivasanGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, USA.
I MakwaraMinistry of Health and Child Care, Harare, Zimbabwe.
Z MachekanyangaWorld Health Organization, Harare, Zimbabwe.
W NyabyendaWorld Health Organization, Geneva, Switzerland.
I MukeredziHarare City Health Department, Harare, Zimbabwe.
M MunyanyiMinistry of Health and Child Care, Harare, Zimbabwe.
A HidleCDC Foundation, Atlanta, USA.
F ChingwenaHarare City Health Department, Harare, Zimbabwe.
C ChigwenaMinistry of Health and Child Care, Harare, Zimbabwe.
P AtuhebweWorld Health Organization, Brazzaville, Republic of the Congo.
H MatzgerWorld Health Organization, Geneva, Switzerland.
R ChigerweHarare City Health Department, Harare, Zimbabwe.
A ShaumCDC Foundation, Atlanta, USA.
K DateGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, USA.
D GaroneMédecins Sans Frontières, Brussels, Belgium.
P ChonziHarare City Health Department, Harare, Zimbabwe.
J BarakUnited Nations Children's Fund, Harare, Zimbabwe.
I PhiriMinistry of Health and Child Care, Harare, Zimbabwe.
M RupfutseWorld Health Organization, Harare, Zimbabwe.
K MasundaHarare City Health Department, Harare, Zimbabwe.
A GasasiraWorld Health Organization, Harare, Zimbabwe.
P ManangaziraMinistry of Health and Child Care, Harare, Zimbabwe.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Introduction: Typhoid fever is a public-health problem in Harare, the capital city of Zimbabwe, with seasonal outbreaks occurring annually since 2010. In 2019, the Ministry of Health and Child Care (MOHCC) organized the first typhoid conjugate vaccination campaign in Africa in response to a recurring typhoid outbreak in a large urban setting. Method: As part of a larger public health response to a typhoid fever outbreak in Harare, Gavi approved in September 2018 a MOHCC request for 340,000 doses of recently prequalified Typbar-TCV to implement a mass vaccination campaign. To select areas for the campaign, typhoid fever surveillance data from January 2016 until June 2018 was reviewed. We collected and analyzed information from the MOHCC and its partners to describe the vaccination campaign planning, implementation, feasibility, administrative coverage and financial costs. Results: The campaign was conducted in nine high-density suburbs of Harare over eight days in February-March 2019 and targeted all children aged 6 months-15 years; however, the target age range was extended up to 45 years in one suburb due to the past high attack rate among adults. A total of 318,698 people were vaccinated, resulting in overall administrative coverage of 85.4 percent. More than 750 community volunteers and personnel from the MOHCC and the Ministry of Education were trained and involved in social mobilization and vaccination activities. The MOHCC used a combination of vaccination strategies (i.e., fixed and mobile immunization sites, a creche and school-based strategy, and door-to-door activities). Financial costs were estimated at US$ 2.39 per dose, including the vaccine and vaccination supplies (US$ 0.79 operational costs per dose excluding vaccine and vaccination supplies). Conclusion: A mass targeted campaign in densely populated urban areas in Harare, using the recently prequalified typhoid conjugate vaccine, was feasible and achieved a high overall coverage in a short period of time.

Indexed as

Financial costsMass vaccination campaignOutbreak responseTyphoid conjugate vaccineTyphoid feverZimbabwe

Identifiers

PMID35983519
PMCPMC9379662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.